INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Purchases 7,690 Shares

INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss bought 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the transaction, the chief financial officer now directly owns 1,275,869 shares of the company’s stock, valued at approximately $8,140,044.22. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

INmune Bio Stock Up 3.1 %

Shares of NASDAQ:INMB opened at $5.55 on Wednesday. INmune Bio, Inc. has a 52 week low of $5.20 and a 52 week high of $14.74. The stock has a market capitalization of $109.79 million, a P/E ratio of -2.89 and a beta of 1.86. The firm has a fifty day simple moving average of $7.35 and a two-hundred day simple moving average of $9.14.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%.

Analyst Upgrades and Downgrades

Separately, Scotiabank assumed coverage on INmune Bio in a report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price objective on the stock.

Hedge Funds Weigh In On INmune Bio

A number of institutional investors and hedge funds have recently modified their holdings of INMB. Financial Advocates Investment Management raised its holdings in INmune Bio by 8.6% during the 4th quarter. Financial Advocates Investment Management now owns 12,500 shares of the company’s stock valued at $141,000 after buying an additional 990 shares during the period. Rhumbline Advisers purchased a new position in INmune Bio during the second quarter worth $121,000. Fermata Advisors LLC increased its position in INmune Bio by 6.9% during the first quarter. Fermata Advisors LLC now owns 31,451 shares of the company’s stock valued at $370,000 after acquiring an additional 2,025 shares during the last quarter. Westside Investment Management Inc. lifted its holdings in shares of INmune Bio by 31.8% in the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after acquiring an additional 10,950 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after acquiring an additional 32,511 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.